Analysts Offer Insights on Healthcare Companies: Avita Medical (RCEL) and CVRx (CVRX)
TipRanksApr 24 09:00 ET
CVRx's (CVRX) Latest Data Favors Barostim's Long-Term Benefits
Yahoo FinanceApr 19 11:14 ET
CVRx, Inc.'s (NASDAQ:CVRX) 26% Cheaper Price Remains In Tune With Revenues
To the annoyance of some shareholders, CVRx, Inc. (NASDAQ:CVRX) shares are down a considerable 26% in the last month, which continues a horrid run for the company. Still, a bad month hasn't complet
Simply Wall StApr 19 07:30 ET
CVRx to Report First Quarter 2024 Financial and Operating Results and Host Conference Call on April 30th, 2024
MINNEAPOLIS, April 16, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing Barostim, an innovative
GlobeNewswireApr 16 16:30 ET
Express News | CVRx Announced Availability Of Additional Data Highlighting Long-term Sustained Benefits Of Barostim In Heart Failure Patients With Reduced Ejection Fraction
Moomoo 24/7Apr 15 07:36 ET
Express News | CVRx Announces Availability of Additional Data Supporting Long-Term Benefits of Barostim
Moomoo 24/7Apr 15 07:30 ET
Both Private Equity Firms Who Control a Good Portion of CVRx, Inc. (NASDAQ:CVRX) Along With Institutions Must Be Dismayed After Last Week's 13% Decrease
Key Insights CVRx's significant private equity firms ownership suggests that the key decisions are influenced by shareholders from the larger public 50% of the business is held by the top 5 sharehol
Simply Wall StMar 27 06:15 ET
CVRx Inc(CVRX.US) Officer Sells US$55,748.23 in Common Stocks
$CVRx Inc(CVRX.US)$ Officer VERRASTRO PAUL sold 2,545 shares of Common Stocks on Feb 20, 2024 at an average price of $21.905 for a total value of $55,748.23.Source: Announcement What is statement of c
moomoo NewsFeb 22 18:46 ET
Analysts' Top Healthcare Picks: CVRx (CVRX), DocGo (DCGO)
TipRanksFeb 1 08:21 ET
Piper Sandler Keeps Their Buy Rating on CVRx (CVRX)
TipRanksFeb 1 08:08 ET
CVRx Full Year 2023 Earnings: EPS Beats Expectations
Yahoo FinanceJan 31 14:16 ET
Craig-Hallum Remains a Buy on CVRx (CVRX)
TipRanksJan 31 08:55 ET
Lake Street Sticks to Their Buy Rating for CVRx (CVRX)
TipRanksJan 31 08:45 ET
CVRx: Nadim Yared Will Retire From the Co and Resign His Bd Seat Concurrent With Hykes' Appointment and Has Agreed to Consult With the Co to Ensure a Seamless Transition >CVRX
CVRx: Nadim Yared Will Retire From the Co and Resign His Bd Seat Concurrent With Hykes' Appointment and Has Agreed to Consult With the Co to Ensure a Seamless Transition >CVRX
Dow JonesJan 31 08:02 ET
Press Release: CVRx Announces Appointment of Kevin Hykes as President and Chief Executive Officer
CVRx Announces Appointment of Kevin Hykes as President and Chief Executive Officer -- Appointment effective February 12 following Nadim Yared's retirement -- Hykes currently serves as Augmedics
Dow JonesJan 31 08:00 ET
Analyst Expectations For CVRx's Future
In the preceding three months, 4 analysts have released ratings for CVRx (NASDAQ:CVRX), presenting a wide array of perspectives from bullish to bearish.In the table below, you'll find a summary of the
BenzingaJan 26 14:00 ET
CVRx Price Target Raised to $33.00/Share From $21.00 by Piper Sandler
CVRx Price Target Raised to $33.00/Share From $21.00 by Piper Sandler
Dow JonesJan 26 13:59 ET
CVRx Is Maintained at Overweight by JP Morgan
CVRx Is Maintained at Overweight by JP Morgan
Dow JonesJan 26 11:03 ET
Express News | JP Morgan Maintains Overweight on CVRx, Raises Price Target to $36
Moomoo 24/7Jan 26 10:53 ET
CVRx Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 01/26/2024 28.77% JP Morgan $31 → $36 Maintains Overweight 12/27/2023 14.46% Lake Street $21 → $32 Maintai
BenzingaJan 26 10:52 ET
No Data
No Data